HCG
IOVA icon

Haven Capital Group’s Iovance Biotherapeutics IOVA Stock Holding History

Haven Capital Group’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-59,143
Closed -$208K – 38
2026
Q1 		$208K Hold
59,143
– – 0.19% 36
2025
Q4 		$161K Sell
59,143
-16,361
-22% -$37.9K 0.15% 34
2025
Q3 		$164K Sell
75,504
-31,008
-29% -$73.2K 0.15% 37
2025
Q2 		$183K Sell
106,512
-15,399
-13% -$38.3K 0.16% 41
2025
Q1 		$406K Sell
121,911
-2,538
-2% -$13.1K 0.45% 28
2024
Q4 		$921K Buy
+124,449
New +$1.15M 0.87% 22

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Haven Capital Group's IOVA Position: Q2 2026 in Review

Haven Capital Group sold out of Iovance Biotherapeutics (IOVA) in Q2 2026, closing a stake of 59,143 shares — an estimated $208K sold.

Haven Capital Group first reported a position in IOVA in Q4 2024 and held it in 6 quarters. The position peaked at $921K in Q4 2024. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Haven Capital Group reported no remaining Iovance Biotherapeutics position as of Q2 2026 after selling out during the quarter.
  • Haven Capital Group sold 59,143 Iovance Biotherapeutics shares in Q2 2026, an estimated $208K.
  • Haven Capital Group first reported a position in Iovance Biotherapeutics in Q4 2024 and held it in 6 quarters.
  • Haven Capital Group's Iovance Biotherapeutics position peaked at $921K in Q4 2024.
  • 292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Haven Capital Group's 13F filing for Q2 2026, filed 10 Jul 2026.